Background
Methods
Patients
Immunohistochemical techniques
Immunohistochemical determination of p-Smad2
Statistical analysis
Results
Relationship between clinicopathological features and phospho-Smad2 expression
Parameter | P-Smad2 |
p-Value | ||
---|---|---|---|---|
High (n = 63) | Low (n = 72) | |||
Gender | ||||
Male | 39 (41.9%) | 54 (58.1%) | N.S. | |
Female | 24 (57.1%) | 18 (42.9%) | ||
Morphologic feature+
| ||||
Type 1 | 6 (37.5%) | 10 (62.5%) | 0.025 | |
Type 2 | 14 (35.0%) | 26 (65.0%) | ||
Type 3 | 17 (45.9%) | 20 (54.1%) | ||
Type 4 | 26 (61.9%) | 16 (38.1%) | ||
T stage | ||||
2 | 7 (25.9%) | 20 (74.1%) | 0.031 | |
3 | 52 (50.0%) | 52 (50.0%) | ||
4 | 4 (100.0%) | 0 (0.00%) | ||
Differentiation | ||||
Intestinal-type | 15 (31.2%) | 33 (68.8%) | 0.011 | |
Diffuse-type | 48 (55.2%) | 39 (44.8%) | ||
Lymph node metastasis+
(Japanese classification) | N0 and N1 | 34 (40.5%) | 50 (59.5%) | 0.047 |
N2 and N3 | 29 (56.9%) | 22 (43.1%) | ||
Lymph node metastasis++
(UICC classification) | N0 and N1 | 31 (36.9%) | 53 (63.1%) | 0.004 |
N2 and N3 | 32 (62.7%) | 19 (37.3%) | ||
Hepatic metastasis | ||||
Negative | 62 (47.0%) | 70 (53.0%) | N.S. | |
Positive | 1 (33.3%) | 2 (66.7%) | ||
Peritoneal metastasis | ||||
Negative | 48 (42.1%) | 66 (57.9%) | 0.017 | |
Positive | 15 (71.4%) | 6 (28.6%) | ||
Peritoneal cytology+++
| ||||
Negative | 36 (40.4%) | 53 (59.6%) | 0.026 | |
Positive | 22 (64.7%) | 12 (35.3%) | ||
Lymphatic invasion | ||||
Ly0 and ly1 | 26 (40.6%) | 38 (59.4%) | N.S. | |
Ly2 and ly3 | 37 (52.1%) | 34 (47.9%) | ||
Venous invasion | ||||
Negative | 50 (45.5%) | 60 (54.5%) | N.S. | |
Positive | 13 (52.0%) | 12 (48.0%) | ||
Clinical stage | ||||
I | 2 (22.2%) | 7 (77.8%) | 0.022 | |
II | 15 (39.5%) | 23 (60.5%) | ||
III | 18 (40.0%) | 27 (60.0%) | ||
IV | 28 (68.7%) | 15 (31.3%) |
Phospho-Smad2 relates with poor prognosis in gastric cancer
Parameter | Risk ratio | 95% Confidence interval |
p-Value |
---|---|---|---|
P-Smad2 expression | 1.650 | 1.005-2.710 | 0.048 |
Low vs. high | |||
Morphologic feature | 5.354 | 3.199-8.963 | < 0.001 |
Type 1, 2, and 3 vs. type 4 | |||
Differentiation | 3.883 | 2.020-7.463 | < 0.001 |
Intestinal-type vs. Diffuse-type | |||
Lymph node metastasis (Japanese classification) | 3.269 | 1.978-5.403 | < 0.001 |
N0 and N1 vs. N2 and N3 | |||
Peritoneal dissemination | 5.534 | 3.056-8.738 | < 0.001 |
Negative vs. positive | |||
Peritoneal cytology | 5.937 | 3.468-10.166 | < 0.001 |
Negative vs. positive | |||
Lymphatic invasion | 2.055 | 1.234-3.421 | 0.006 |
Ly0 and ly1 vs. ly2 and ly3 | |||
Clinical Stage | 6.901 | 4.088-11.651 | < 0.001 |
I, II, and III vs. IV |
Parameter | Risk ratio | 95% Confidence interval |
p-Value |
---|---|---|---|
P-Smad2 expression | 0.627 | 0.347-1.133 | 0.122 |
Low vs. high | |||
Morphologic feature | 2.325 | 1.221-4.388 | 0.010 |
Type 1, 2, and 3 vs. type 4 | |||
Differentiation | 2.807 | 1.251-6.298 | 0.012 |
Intestinal-type vs. Diffuse-type | |||
Lymph node metastasis (Japanese classification) | 1.387 | 0.689-2.794 | 0.360 |
N0 and N1 vs. N2 and N3 | |||
Peritoneal dissemination | 1.097 | 0.549-2.193 | 0.793 |
Negative vs. positive | |||
Lymphatic invasion | 1.394 | 0.805-2.413 | 0.235 |
Ly0 and ly1 vs. ly2 and ly3 | |||
Clinical Stage | 4.382 | 1.924-9.978 | < 0.001 |
I, II, and III vs. IV |